NCT03053596View on ClinicalTrials.gov

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

CompletedOBSERVATIONAL

Enrollment

102

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 1, 2019

Study Completion Date

October 8, 2019

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE

DEB-TACE using anthracyclin loaded LifePearl™

The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.

Trial Locations (7)

Unknown

Cliniques Universitaires Saint Luc, Brussels

Hôpital Erasme, Brussels

Hôpital Beaujon, Clinchamp

CHRU Lille, Lille

Hôpital Universitaire Saint-Eloi, Montpellier

Hôpital L'Archet II, Nice

Institut Gustave Roussy, Villejuif

All Listed Sponsors

lead

Terumo Europe N.V.

INDUSTRY

NCT03053596 - LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry) | Biotech Hunter | Biotech Hunter